Clinical Trials - May 6, 2016
Nordic Nanovector enrols first patient in extended Betalutin study
Nordic Nanovector announces that the first patient has been enrolled into one of the two new arms of its expanded Lymrit 37-01 clinical study with Betalutin. Betalutin is a novel anti-CD37 targeting Antibody Radionuclide Conjugate in development for the treatment of major types of non-Hodgkin’s lymphoma (NHL), including Follicular Lymphoma (FL). The new arm (Arm 3) […]
Clinical Trials - April 18, 2016
Nordic Nanovector’s Betalutin shows promise
Nordic Nanovector’s Betalutin continues to show promising efficacy and increasing Duration of Response. Nordic Nanovector, a biotechnology company focusing on the development of novel targeted therapeutics in haematology and oncology, announces updated results of its ongoing Phase 1/2 study with Betalutin in relapsed non-Hodgkin lymphoma (NHL) patients. Betalutin was generally well tolerated and showed a […]